Skip to main content

Search

Welcome to Janssen Canada

VISIT JANSSEN GLOBAL

Title

Media

08, November, 2019

Toronto

Janssen Announces Health Canada Approval of IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia

04, November, 2019

Toronto

Janssen Announces Health Canada Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible

13, August, 2019

Toronto

Janssen Inc. Statement on Final Amendments to PMPRB

05, June, 2019

Toronto

Janssen Inc. Statement on British Columbia (B.C.) Biosimilars Initiative

29, May, 2019

Toronto

Janssen Announces Health Canada Approval of TREMFYA ONE-PRESS™ (guselkumab) – A Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

15, April, 2019

Melbourne

INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

08, March, 2019

Toronto

IMBRUVICA® (ibrutinib) Combination Regimen to Treat Waldenström’s Macroglobulinemia Approved Through Health Canada Priority Review

16, December, 2018

Toronto

Health Canada Approves DARZALEX® (daratumumab) for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

17, October, 2018

Toronto

Health Canada has approved INVOKANA®* (canagliflozin) for reduction of major adverse cardiovascular events (MACE), the first SGLT2 inhibitor in Canada to receive this indication1

04, July, 2018

Toronto, Ontario

Health Canada Approves ERLEADA™* (apalutamide tablets), the First Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer